Barclays’s SELLAS Life Sciences SLS Stock Holding History

Barclays’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.09M	Buy	88,866 +53,083	+148%	+$665K	﹤0.01%	2985
2026 Q2	$528K	Buy	35,783 +3,371	+10%	+$23.3K	﹤0.01%	3185
2026 Q1	$137K	Sell	32,412 -478,622	-94%	-$2.14M	﹤0.01%	3893
2025 Q4	$1.93M	Buy	511,034 +328,354	+180%	+$638K	﹤0.01%	2958
2025 Q3	$294K	Buy	182,680 +9,877	+6%	+$17.6K	﹤0.01%	4117
2025 Q2	$378K	Buy	+172,803	New	+$265K	﹤0.01%	3912
2019 Q4	–	Sell	-17	Closed	–	–	6767
2019 Q3	$0	Buy	+17	New	+$125	﹤0.01%	7088
2019 Q1	–	Sell	-2	Closed	–	–	7300
2018 Q4	$0	Buy	+2	New	+$155	﹤0.01%	7298
2018 Q2	–	Sell	-1	Closed	–	–	7250
2018 Q1	$0	Buy	+1	New	+$285	﹤0.01%	7305
2017 Q2	–	Sell	-8	Closed	-$7K	–	6899
2017 Q1	$7K	Buy	+8	New	+$13.2K	﹤0.01%	6196
2016 Q4	–	Hold	0	–	–	–	6488

Other funds holding SLS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

DAGCO Inc Westlake, Ohio $576M AUM 21.79% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Opus Capital Group Cincinnati, Ohio $1.02B AUM 13.75% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Barclays's SLS Position: Q3 2026 in Review

Barclays increased its SELLAS Life Sciences (SLS) stake by 148% in Q3 2026, buying an estimated $665K and bringing the position to 88,866 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

Barclays first reported a position in SLS in Q1 2017 and has held it in 10 quarters since. The position peaked at $1.93M in Q4 2025. 112 funds tracked by Wall St. Rank hold SLS as of Q3 2026.

Barclays held 88,866 shares of SELLAS Life Sciences worth $1.09M as of Q3 2026.
Barclays bought 53,083 SELLAS Life Sciences shares in Q3 2026, an estimated $665K.
SELLAS Life Sciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2985 holding.
Barclays first reported a position in SELLAS Life Sciences in Q1 2017 and has held it in 10 quarters since.
Barclays's SELLAS Life Sciences position peaked at $1.93M in Q4 2025.
112 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.